About Circadian-associated transcriptional repressor
Circadian-associated transcriptional repressor (CIART) is a protein
from Homo sapiens identified by UniProt accession
Q8N365, 385 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | Circadian-associated transcriptional repressor |
| UniProt accession | Q8N365 |
| Gene | CIART |
| Organism | Homo sapiens |
| Length | 385 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.15
- appendicular lean mass · score 0.12
- basophil count · score 0.09
- creatinine measurement · score 0.09
- neutrophil count · score 0.09
- circadian rhythm · score 0.07
- leukocyte count · score 0.06
- asthma · score 0.06
- glomerular filtration rate · score 0.06
- low density lipoprotein cholesterol measurement · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N365-F1 | alphafold | PREDICTED | 54.53 | — |
Amino-acid sequence (385 residues)
MDSPSSVSSY SSYSLSSSFP TSPVNSDFGF PSDSEREDKG AHGPRPDTVG QRGGSRPSPG PIRCRHRSKV SGNQHTPSHP KQRGSASPMA GSGAKRSRDG ELETSLNTQG CTTEGDLLFA QKCKELQGFI PPLTDLLNGL KMGRFERGLS SFQQSVAMDR IQRIVGVLQK PQMGERYLGT LLQVEGMLKT WFPQIAAQKS SLGGGKHQLT KHFPSHHSDS AASSPASPME KMDQTQLGHL ALKPKQPWHL TQWPAMNLTW IHTTPICNPP LSSPGTISFS HGPLGTGTGI GVILFLQHGV QPFTHSAPTT PVPPTTASPV IPGEPMKLSG EGPRCYSLPV TLPSDWSYTL SPPSLPTLAR KMTIGHREQQ RSHPPVAADA HLLNL
Explore Circadian-associated transcriptional repressor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets